When was Rubicon founded?

Rubicon was founded in 2000 and raised its 1st funding round 7 years after it was founded.

Where is Rubicon located?

Rubicon is headquartered in Mumbai, India. It is registered at MEDONE HOUSE, B-75, ROAD NO. 33 WAGLE ESTATE, THANE WEST, Thane, THANE, Maharashtra, India, 400604.

Which legal entities is Rubicon associated with?

Rubicon is associated with RUBICON RESEARCH LIMITED and 4 others.

How many employees does Rubicon have?

As of Sep 30, 2026, the latest employee count at Rubicon is 1239.

Is Rubicon a funded company?

Rubicon is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Aug 10, 2007.

When was the latest funding round of Rubicon?

Rubicon's latest funding was a $***** Series A round on Aug 10, 2007, with participation from 2 investors. Its primary sector is Traditional Pharmaceuticals. In India, the Traditional Pharmaceuticals sector has seen $800M in funding in 2026 to date.

Where does Rubicon rank among its competitors?

Rubicon ranks 29th amongst 1247 active competitors, of which 43 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Wockhardt, which secured $118M in Nov, 2024.

Who are the top competitors of Rubicon?

Rubicon's top competitors include Bayer, Teva Pharmaceuticals and Biological E. Among them, Wockhardt secured the most recent funding round in November, 2024.

Rubicon - 2026 Company Profile, Team, Funding, Competitors & Financials

Rubicon is a public company based in Mumbai (India), founded in 2000 by Maharukh Rustomjee and Sudhir Pilgaonkar. It operates as a CDMO offering drug development services through its proprietary drug delivery technologies. Rubicon has raised $4.62M in funding from Kotak Private Equity Group. The company has 1247 active competitors, including 43 funded and 337 that have exited. Its top competitors include companies like Bayer, Teva Pharmaceuticals and Biological E.

Company Details

Rubicon Research is focussed on providing a suite of contract development and manufacturing services during drug development including formulation development, analytical development, stability evaluations and technology transfer. It has developed proprietary technologies which assist for bioavailability enhancement, gastric retention, taste masking, and customising the release profiles. It claims to develop alternate dosage forms such as orally disintegrating tablets, dispersible tablets and various paediatric dosage forms.They offer contract development (for oral solids and liquids, topicals, creams and gels, ophthalmic and nasal preparations) as well as contract manufacturing services (for oral solid dosage forms). They mainly export to US and Europe and their drugs cater to a wide variety of therapeutic areas such as CNS, cardiology, cough, cold and anti-allergy, nutritional dietary supplements, anti-inflammatory, metabolics and others. Their clientele includes Pfizer, Novartis and Solvay.

Website: rubicon.co.in
Email ID: *****@rubicon.co.in
Registered Address: MEDONE HOUSE, B-75, ROAD NO. 33 WAGLE ESTATE, THANE WEST, Thane, THANE, Maharashtra, India, 400604

Key Metrics

Founded Year

2000

Location

Mumbai, India

Stage

Public

Total Funding

$4.62M in 1 round

Latest Funding Round

Series A, Aug 10, 2007, $*****

Investors

Kotak Private Equity Group & 4 more

Ranked

29^th among 1247 active competitors

Employee Count

1,239 as on Sep 30, 2026

Investment & Acquisitions

Arinna Lifesciences

Similar Companies

Teva Pharmaceuticals & 1461 more

Exit Details

Public

View Rubicon's full profile

Rubicon is associated with 5 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count
RUBICON ACADEMY LLP CIN: AAS-9364 , India, Active	Jul 18, 2020	0 - ₹10 Cr (As on Mar 31, 2025)	-
RUBICON RESEARCH LIMITED CIN: 4417021 , United Kingdom, Active	Apr 14, 2002	-	3 (As on Apr 30, 2024)
RUBICON CONSUMER HEALTHCARE PRIVATE LIMITED CIN: U24304MH2020PTC340052 , India, Active	May 27, 2020	0 - ₹10 Cr (As on Mar 31, 2025)	5 (As on Aug 31, 2023)
GENERAL ATLANTIC SINGAPORE RR PTE. LTD UEN: 201830439C , Singapore, Active	Sep 04, 2018	-	-
RUBICON RESEARCH LIMITED CIN: L73100MH1999PLC119744 , India, Active	May 06, 1999	₹1,000+ Cr (As on Mar 31, 2026)	1191 (As on Aug 01, 2025)

Rubicon got listed on Oct 16, 2025.

Click here to take a look at Rubicon's IPO in detail

Rubicon has raised a total funding of $4.62M over 1 round. Its latest funding round was a Series A round on Aug 10, 2007 for $*****. 2 investors participated in its latest round. Rubicon has 3 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Rubicon:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 10, 2007	6000560	Series A	4162147	6690040	3681231	3128028

Access funding benchmarks and valuations. Sign up today!

View details of Rubicon's funding rounds and investors

The founders of Rubicon are Maharukh Rustomjee and Sudhir Pilgaonkar.

Here are the details of Rubicon's key team members:

Maharukh Rustomjee: Co-Founder of Rubicon and founder of 2 other companies, Amaterasu and Skineasi. They are also an angel investor in 1 startup.
Sudhir Pilgaonkar: Co-Founder of Rubicon.
Contact Info: 1 email address

View details of Rubicon's Founder profiles and Board Members

Rubicon's employee count trend

Rubicon has 1,239 employees as of Sep 26. Here is Rubicon's employee count trend over the years:

Uncover Rubicon's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Rubicon include Bayer, Teva Pharmaceuticals and Biological E. Here is the list of Top 10 competitors of Rubicon, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Bayer 1863, Leverkusen (Germany), Public	Manufacturer of drugs	-	Digital Pharma Lab, B Capital Fund & 9 others	76/100
2nd	Teva Pharmaceuticals 1901, Petah Tikva (Israel), Public	Traditional company engaged in manufacturing generics	$500M	Berkshire Hathaway, JANA Partners & 3 others	75/100
3rd	Biological E 1953, Hyderabad (India), Late Stage	Developer of vaccines for treating multiple diseases	$60M	Gates, IFC & 3 others	75/100
4th	Wockhardt 1967, Mumbai (India), Public	Manufacturer of pharmaceuticals, biotechnology products, and active pharmaceutical ingredients	-	HDFC Mutual Fund, Tata Mutual Fund & 12 others	72/100
5th	Lupin 1968, Mumbai (India), Public	Manufacturer of pharmaceutical products, including generics, biosimilars, and active pharmaceutical ingredients	$6.64M	Cipher International, AbbVie & 5 others	71/100
6th	Cipla 1935, Mumbai (India), Public	Manufacturer of APIs, generic drugs, and formulation development services	-	MUFG, Eight Roads Ventures & 3 others	69/100
7th	The Alvogen 2009, Morristown (United States), Acquired	Developer and marketer of pharmaceutical products	$156M	Morgan Stanley, IMM Private Equity & 11 others	69/100
8th	Emcure 1981, Pune (India), Public	Developer, manufacturer, and markets a broad range of pharmaceutical products	$50M	Blackstone, Bain Capital	68/100
9th	Amneal 2002, Bridgewater (United States), Public	Manufacturer of generics formulations	-	Tarsadia, GE Capital & 2 others	68/100
10th	Strides Pharma Science 1990, Bengaluru (India), Public	Manufacturer of generic pharmaceutical products and various specialty medical formulations	-	InvAscent, Oman India Joint Investment Fund ... & 3 others	68/100
29th	Rubicon 2000, Mumbai (India), Public	CDMO offering drug development services through its proprietary drug delivery technologies	$4.62M	Kotak Private Equity Group, Terentia & 3 others	62/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Rubicon's competitors? Click here to see the top ones

Founders (largest shareholder) own 48.42%, Funds own 23.84%, Other People own 22.91% and Other Investors own 4.84%. The net worth of Rubicon's founders is INR 38.6Cr as of Mar 27, 2008. The cap table displayed below is for RUBICON RESEARCH LIMITED which is the legal entity associated with Rubicon.

Shareholders Name	Post Round Holding %	Net worth	Cumulative Investment	Realised Returns	Unrealised Returns	Return Multiple
Founder	48.42%	38.6Cr	8804042	2090670	6023196	1088737
Sudhir Pilgaonkar	3330050	8828057	3496120	1337204	3310031	2578525
Fund	23.84%	19Cr	4656894	9955542	5600527	8448967
Kotak Mahindra Bank	6847597	5650493	1613877	7484268	9793351	4931316
Other People	22.91%	18.3Cr	9576683	3814595	6616131	1818436
Other Investors	4.84%	3.86Cr	3269	4367	5529	7344
Total	100.00%	79.8Cr	1543612	4438679	5349072	1082731